

Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/99242/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Kariuki, Benson ORCID: <https://orcid.org/0000-0002-8658-3897> and El-Hiti, Gamal 2017. A reversible single-crystal to single-crystal thermal phase transformation of 3-(2-Bromo-4-(1-methylethyl)phenyl)-1,1-dimethyl urea. Crystals 7 (3) , 75. 10.3390/cryst7030075 file

Publishers page: <http://dx.doi.org/10.3390/cryst7030075>
<<http://dx.doi.org/10.3390/cryst7030075>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies.

See

<http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Article

A Reversible Single-Crystal to Single-Crystal Thermal Phase Transformation of 3-(2-Bromo-4-(1-methylethyl)phenyl)-1,1-dimethyl urea

Benson M. Kariuki ^{1,*} and Gamal A. El-Hiti ^{2,*}¹ School of Chemistry, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, UK² Cornea Research Chair, Department of Optometry, College of Applied Medical Sciences, King Saud University, P.O. Box 10219, Riyadh 11433, Saudi Arabia

* Correspondence: kariukib@cardiff.ac.uk (B.M.K.); gelhiti@ksu.edu.sa (G.A.E.-H.); Tel.: +966-11469-3778 (G.A.E.-H.); Fax: +966-11469-3536 (G.A.E.-H.)

Academic Editors: Alberto Girlando and Anna Painelli

Received: 13 February 2017; Accepted: 1 March 2017; Published: 4 March 2017

Abstract: 3-(2-Bromo-4-(1-methylethyl)phenyl)-1,1-dimethylurea was synthesized and structurally characterized at 296 K, 200 K and 140 K. A reversible thermal phase transformation was observed at ~170–180 K. On cooling, the structure transforms from a monoclinic to a triclinic crystal system. The isopropyl group is disordered above the phase transition temperature but is ordered below the transition temperature.

Keywords: crystal-to-crystal; 1,1-dimethylurea; reversible; phase transition; thermal

1. Introduction

Urea-containing compounds are established as precursors for several biologically active agents [1–4]. Various efficient procedures have been used for the synthesis of ureas [5–14]. The most recent examples involve reactions of primary amines with *S,S*-dimethyl dithiocarbonate in water followed by reactions with secondary amines [15]; reactions of aromatic amines with secondary amines in the presence of carbon monoxide, sulfur and oxygen in dimethylformamide [16]; and reactions of benzylamine with secondary amines in the presence of a ruthenium catalyst [17]. Other synthetic methods involve the catalytic reaction of carboxylic acids with hydroxylamine hydrochloride followed by reaction with primary amines [18]; conversion of aryl chlorides to the corresponding isocyanates using a palladium catalyst followed by reaction with secondary amines [19]; and conversion of isonitriles to the corresponding isocyanates using dimethyl sulfoxide followed by reaction with *tert*-butylamine [20]. The reaction of aromatic ureas with a lithium reagent followed by electrophiles is one of the most common methods used to produce substituted derivatives [21–25].

Polymorphic phase transformation is an area of continued research interest [26–35]. The transformation process is an indication of the fine balance in the interactions within the crystal that can be tipped by a relatively small change in conditions [36,37]. In most cases, such transformations proceed with loss of single-crystal integrity, such that a single crystal of the starting solid phase transforms into a polycrystalline sample of the product. Where the structural reorganization involved is small, transformation of a single crystal of the starting material may produce a single crystal of the product phase. Additionally, the process may be reversible but this is rare in organic crystals [30–35]. Enantiotropic behavior has been observed unsurprisingly between forms with very similar unit cell parameters [31,32], but transformation more commonly involves larger shifts in the parameters [33–35]. Polymorphism and polymorphic phase transformations are difficult to predict and are often discovered fortuitously [26].

In the current paper, we investigated the synthesis, characterization and reversible single-crystal to single-crystal thermal phase transformation of 3-(2-bromo-4-(1-methylethyl)phenyl)-1,1-dimethylurea.

2. Results and Discussion

Phase transformation: In the process of characterization of 3-(2-bromo-4-(1-methylethyl)phenyl)-1,1-dimethylurea following synthesis, the crystal structure was determined initially at 296 K. The structure, **1_{HT}** (Table 1), is monoclinic, $P2_1/c$ (with unit cell parameters $a = 12.117(2)$ Å, $b = 10.0335(10)$ Å, $c = 12.816(2)$ Å, $\beta = 117.82(2)^\circ$, volume = $1377.9(5)$ Å³). Data collection performed at 140 K in an attempt to improve the quality of the refined structure revealed a different structure (**2**), indicating that a phase transition had occurred on cooling. Structure **2** is triclinic, $P\bar{1}$, with unit cell parameters $a = 11.8916(7)$ Å, $b = 9.9293(6)$ Å, $c = 12.4631(7)$ Å, $\alpha = 92.720(5)^\circ$, $\beta = 116.190(5)^\circ$, $\gamma = 81.000(5)^\circ$, volume = $1303.86(14)$ Å³. (This unit cell has been used for ease of comparison with the monoclinic structure **1**. The reduced cell is $9.9290(6)$ Å, $11.8920(7)$ Å, $12.4630(7)$ Å, $63.810(5)^\circ$, $87.280(5)^\circ$, $81.000(5)^\circ$). The matrix for the transformation from **2** to **1** is (1.0072, −0.189, −0.0073, 0, 1.0088, 0, −0.0149, 0.063, 1.0164).

Table 1. Experimental and structure refinement data.

Identification Code	1_{HT}	1_{LT}	2
Empirical formula	C ₁₂ H ₁₇ BrN ₂ O	C ₁₂ H ₁₇ BrN ₂ O	C ₁₂ H ₁₇ BrN ₂ O
Formula weight	285.18	285.18	285.18
Temperature (K)	296(2)	200(2)	140(2)
Wavelength (Å)	0.71073	0.71073	0.71073
Crystal system	Monoclinic	Monoclinic	Triclinic
Space group	$P2_1/c$	$P2_1/c$	$P\bar{1}$
a (Å)	12.117(2)	11.8696(12)	11.8916
b (Å)	10.0335(10)	10.0171(7)	9.9293(6)
c (Å)	12.816(2)	12.7306(12)	12.4631(7)
α (°)	90	90	92.720(5)
β (°)	117.82(2)	117.199(13)	116.190(5)
γ (°)	90	90	81.000(5)
Volume (Å ³)	1377.9(5)	1346.3(3)	1303.86(14)
Z	4	4	4
σ_{cal} (Mg/m ³)	1.375	1.407	1.453
μ (mm ^{−1})	2.967	3.037	3.135
$F(000)$	584	584	584
Crystal size (mm ³)	$0.272 \times 0.177 \times 0.122$	$0.309 \times 0.170 \times 0.106$	$0.301 \times 0.209 \times 0.099$
Reflections collected	4752	7310	11649
Independent reflections	2718	3229	11030
$R(\text{int})$	0.0622	0.0284	0.0751
Data/restraints/parameters	2718/109/166	3229/110/170	11,649/0/297
Goodness-of-fit on F^2	0.813	1.036	0.913
$R1[I > 2\sigma(I)]$	0.0614	0.0673	0.0446
wR2	0.1619	0.1644	0.1029
$R1$ (all data)	0.1744	0.1117	0.0850
wR2	0.1827	0.1961	0.1081

The transformation occurs in a single-crystal to single-crystal manner, so it was possible to determine the unit cell parameters as a function of temperature. A plot of the cell parameters recorded for a single crystal shows a discontinuity in the 170–180 K temperature range (Figure 1). Notably, the transformation occurs reversibly. Thus, the monoclinic structure (**1_{LT}**) discussed below was determined after cooling a crystal past the transition temperature to 150 K, before warming it again to 200 K.




Figure 1. A plot of the unit cell parameters as a function of temperature. The dotted vertical line indicates the phase transition point.

Monoclinic structure: The asymmetric unit of **1_{LT}** consists of one molecule of 3-(2-bromo-4-(1-methylethyl)phenyl)-1,1-dimethylurea (Figure 2a). In the molecule, the angle between the planes through the bromophenyl and dimethylurea groups is $59.24(16)^\circ$. The isopropyl group is disordered with refined occupancies of 0.725(16) and 0.275(16) for the two components. The most acute torsion angles for the isopropyl group are $C5-C4-C7-C9 = -46.3(11)^\circ$ and $C3-C4-C7A-C8A = -61.6(11)^\circ$ for the major and minor components, respectively. In the structure (Figure 2b), chains of molecules are formed along [010] by N-H...O hydrogen bonds (with the geometry $N1-H1...O1 = 143.8^\circ$, $N1...O1 = 2.869(4) \text{ \AA}$).




Figure 2. (a) An ortep representation of the asymmetric unit of **1_{LT}** showing the disordered isopropyl group; (b) Crystal packing viewed down the *a* axis with hydrogen atoms and one disorder component omitted for clarity. Hydrogen bonds are shown as dashed lines.

Triclinic structure: Structure **2** has two independent molecules in the asymmetric unit (Figure 3a). The angles between the planes through the bromobenzene and dimethylurea groups are $69.25(9)^\circ$ and $49.51(11)^\circ$ for the two molecules. It is notable that the average of these values for the interplanar angles

is the same as that for the single independent molecule in **1_{LT}**. Unlike in **1_{LT}**, the isopropyl groups are ordered in **2**, and the most acute torsion angles are $C3-C4-C7-C8 = 51.9(5)^\circ$ and $C17-C16-C19-C20 = -28.6(5)^\circ$. In the structure (Figure 3b), chains of $N-H \cdots O$ hydrogen-bonded molecules are formed along [010].

The two molecules alternate along the chain leading to the formation of two hydrogen bonding interactions (with the geometries $N1-H1 \cdots O2 = 149.8^\circ$, $N1 \cdots O2 = 2.872(4) \text{ \AA}$ and $N3-H3A \cdots O1 = 134.5^\circ$, $N3 \cdots O1 = 2.799(4) \text{ \AA}$). Although not identical, the chains of the hydrogen-bonded molecules are similar in both **1** and **2** as indicated by the overlay plot in Figure 4.




Figure 3. (a) An ortep representation of the asymmetric unit of **2** showing the two molecules in the asymmetric unit; (b) Crystal packing viewed down the *a* axis with the hydrogen atoms omitted for clarity. Hydrogen bonds are shown as dashed lines.




Figure 4. An overlay of the hydrogen bonded chains from **1_{LT}** (red) and **2** (blue). The minor disorder component in **1** has been omitted for clarity.

On cooling the crystal from 296 K, the structure transforms from a monoclinic to a triclinic crystal system, retaining a similar unit cell volume. The single molecule in the asymmetric unit of the monoclinic structure above the phase transition temperature has a disordered isopropyl group. The refined ratios of the disordered components of the isopropyl group at 296 K and 200 K are 0.645(15)/0.355(15) and 0.725(16)/0.275(16), respectively. The values are significantly different from the 1:1 ratio of the two conformations of the independent molecules observed in the ordered structure of **2**. This suggests that the isopropyl group has some rotational freedom about the C-C(CH₃)₂ bond. Disorder in isopropyl groups is common, but significant isopropyl rotation is expected to occur only in exceptional circumstances as, for example, observed in 1-(benzoyl)-3-((5'-isopropyl-2'-methylphenoxy)acetamino) thiourea [30].

3. Experimental Section

3.1. General

Melting point determination was performed on a Gallenkamp melting point apparatus. ¹H (400 MHz) and ¹³C NMR (100 MHz) spectra were recorded on a Bruker AV400 spectrometer. The chemical ionization (ammonia) mass spectrum was recorded on a Quattro II spectrometer at 50 eV. Accurate mass data were recorded on a MAT900 instrument.

3.2. Synthesis of 3-(2-Bromo-4-(1-methylethyl)phenyl)-1,1-dimethylurea

The title compound was produced from reaction of 2-bromo-4-(1-methylethyl)aniline (10 mmol) and dimethylcarbamoyl chloride (11 mmol) in dichloromethane (40 mL) under reflux for 1 h in the presence of excess triethylamine (15 mmol). On cooling, the solvent was removed under reduced pressure and the residue obtained was purified by crystallization from diethyl ether to give the title compound as colourless crystals. Mp 93–94 °C. ¹H NMR (CDCl₃, 400 MHz) δ 8.08 (d, *J* = 7.3 Hz, 1 H, H-6), 7.33 (s, 1 H, H-3), 7.15 (d, *J* = 7.3 Hz, 1 H, H-5), 6.91 (br s, exch., 1 H, NH), 3.06 (s, 6 H, N(CH₃)₂), 2.83 (septet, *J* = 7.2 Hz, 1 H, CH), 1.20 (d, *J* = 7.2 Hz, 6 H, CH(CH₃)₂). ¹³C NMR (CDCl₃, 100 MHz) δ 156.1 (s, C=O), 135.2 (s, C-4), 133.3 (s, C-1), 131.3 (d, C-3), 125.0 (d, C-5), 123.9 (s, C-6), 121.4 (d, C-2), 35.1 (q, N(CH₃)₂), 31.8 (d, CH); 24.0 (q, CH(CH₃)₂). EI-MS: *m/z* (%) 284 (M⁺, 5), 177 (11), 72 (100); CI-MS: *m/z* (%) 302 ([M + NH₄]⁺, 2), 285 (MH⁺, 100), 177 (22), 72 (100). HRMS (CI): calculated for C₁₂H₁₇BrN₂O (MH⁺): 285.0603; found: 285.0603. IR (KBr) ν_{max} 3292, 2990, 2496, 1690, 1580, 1520, 1480 cm^{−1}. Anal. Calcd for C₁₂H₁₇BrN₂O: C, 50.54; H, 5.96; N, 9.82. Found: C, 50.34; H, 5.83; N, 9.97%.

3.3. Structure Determination

Single-crystal XRD data were collected on an Agilent SuperNova Dual Atlas diffractometer with a mirror monochromator [Mo (λ = 0.7107 Å)] equipped with a Cryosystems cooling apparatus. The crystal structures were solved and refined using SHELX [38]. Non-hydrogen atoms were refined with anisotropic displacement parameters. All hydrogen atoms were placed in calculated positions and refined using a riding model. Methyl C–H bonds were fixed at 0.98 Å, with displacement parameters 1.5 times U_{eq}(C), and were allowed to spin about the C–C bond. Aromatic C–H distances were set to 0.95 Å and their U(iso) set to 1.2 times the U_{eq} for the atoms to which they are bonded. The disordered isopropyl group in **1** was refined with two components and restrained geometry. Crystal data, data collection and structure refinement details are summarized in Table 1. CCDC 1532132–1532134 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via <http://www.ccdc.cam.ac.uk/conts/retrieving.html> (or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK; Fax: +44 1223 336033; E-mail: deposit@ccdc.cam.ac.uk).

4. Conclusions

3-(2-Bromo-4-(1-methylethyl)phenyl)-1,1-dimethylurea was synthesized and its structure was established at 296 K, 200 K and 140 K. A phase transformation was observed at ~170–180 K on cooling

the crystal. The structure transforms from a monoclinic to a triclinic crystal system in a single-crystal to single-crystal manner, retaining a similar unit cell volume. The transformation is reversible on warming. The isopropyl group is disordered above the phase transition temperature but is ordered below the transition temperature.

Acknowledgments: The project was supported by King Saud University, Deanship of Scientific Research, Research Chair and Cardiff University.

Author Contributions: Gamal A. El-Hiti performed the synthesis of the title compound and established its structure by NMR, mass spectroscopy and analytical data. Benson M. Kariuki carried out the X-ray structure determination and thermal phase transformation of the title compound. Both authors wrote the paper.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Kocyigit-Kaymakcioglu, B.; Celen, A.O.; Tabanca, N.; Ali, A.; Khan, S.I.; Khan, I.A.; Wedge, D.E. Synthesis and biological activity of substituted urea and thiourea derivatives containing 1,2,4-triazole moieties. *Molecules* **2013**, *18*, 3562–3576. [[CrossRef](#)] [[PubMed](#)]
2. Khan, K.M.; Saeed, S.; Ali, M.; Gohar, M.; Zahid, J.; Khan, A.; Perveen, S.; Choudhary, M.I. Unsymmetrically disubstituted urea derivatives: A potent class of antiglycating agents. *Bioorg. Med. Chem.* **2009**, *17*, 2447–2451. [[CrossRef](#)] [[PubMed](#)]
3. Dos Santos, L.; Lima, L.A.; Cechinel-Filho, V.; Correa, R.; Buzzi, F.d.C.; Nunes, R.J. Synthesis of new 1-phenyl-3-{4-[(2E)-3-phenylprop-2-enoyl]phenyl}-thiourea and urea derivatives with anti-nociceptive activity. *Bioorg. Med. Chem.* **2008**, *16*, 8526–8534. [[CrossRef](#)] [[PubMed](#)]
4. Kozikowski, A.P.; Zhang, J.; Nan, F.; Petukhov, P.A.; Grajkowska, E.; Wroblewski, J.T.; Yamamoto, T.; Bzdega, T.; Wroblewska, B.; Neale, J.H. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: Efficacy as analgesic agents. *J. Med. Chem.* **2004**, *47*, 1729–1738. [[CrossRef](#)] [[PubMed](#)]
5. Hemantha, H.P.; Chennakrishnaireddy, G.; Vishwanatha, T.M.; Sureshababu, V.V. One-pot synthesis of ureido peptides and urea-tethered glycosylated amino acids employing Deoxo-Fluor and TMSN₃. *Synlett* **2009**, 407–410. [[CrossRef](#)]
6. Carnaroglio, D.; Martina, K.; Palmisano, G.; Penoni, A.; Domini, C.; Cravotto, G. One-pot sequential synthesis of isocyanates and urea derivatives via a microwave-assisted Staudinger-aza-Wittig reaction. *Beilstein J. Org. Chem.* **2013**, *9*, 2378–2386. [[CrossRef](#)] [[PubMed](#)]
7. Han, C.; Porco, J.A., Jr. Synthesis of carbamates and ureas using Zr(IV)-catalyzed exchange processes. *Org. Lett.* **2007**, *9*, 1517–1520. [[CrossRef](#)] [[PubMed](#)]
8. Wu, C.; Cheng, H.; Liu, R.; Wang, Q.; Hao, Y.; Yu, Y.; Zhao, F. Synthesis of urea derivatives from amines and CO₂ in the absence of catalyst and solvent. *Green Chem.* **2010**, *12*, 1811–1816. [[CrossRef](#)]
9. Marinescu, L.; Thinggaard, J.; Thomsen, I.B.; Bols, M. Radical azidonation of aldehydes. *J. Org. Chem.* **2003**, *68*, 9453–9455. [[CrossRef](#)] [[PubMed](#)]
10. Padiya, K.J.; Gavade, S.; Kardile, B.; Tiwari, M.; Bajare, S.; Mane, M.; Gaware, V.; Varghese, S.; Harel, D.; Kurhade, S. Unprecedented “in water” imidazole carbonylation: paradigm shift for preparation of urea and carbamate. *Org. Lett.* **2012**, *14*, 2814–2817. [[CrossRef](#)] [[PubMed](#)]
11. Vasantha, B.; Hemantha, H.P.; Sureshababu, V.V. 1-Propanephosphonic acid cyclic anhydride (T3P) as an efficient promoter for the Lossen rearrangement: Application to the synthesis of urea and carbamate derivatives. *Synthesis* **2010**, 2990–2996. [[CrossRef](#)]
12. Dube, P.; Nathel, N.F.F.; Vetelino, M.; Couturier, M.; Aboussafy, C.L.; Pichette, S.; Jorgensen, M.L.; Hardink, M. Carbonyldiimidazole-mediated Lossen rearrangement. *Org. Lett.* **2009**, *11*, 5622–5625. [[CrossRef](#)] [[PubMed](#)]
13. Paz, J.; Perez-Balado, C.; Iglesias, B.; Munoz, L. Different reactivity of hydroxylamine with carbamoyl azides and carbamoyl cyanides: Synthesis of hydroxyureas and carbamoyl amidoximes. *J. Org. Chem.* **2010**, *75*, 8039–8047. [[CrossRef](#)] [[PubMed](#)]
14. Spyropoulos, C.; Kokotos, C.G. One-pot synthesis of ureas from Boc-protected amines. *J. Org. Chem.* **2014**, *79*, 4477–4483. [[CrossRef](#)] [[PubMed](#)]

15. Artuso, E.; Degani, I.; Fochi, R.; Magistris, C. Preparation of mono-, di-, and trisubstituted ureas by carbonylation of aliphatic amines with *S,S*-dimethyl dithiocarbonate. *Synthesis* **2007**, 3497–3506. [[CrossRef](#)]
16. Mizuno, T.; Nakai, T.; Mihara, M. Synthesis of unsymmetrical ureas by sulfur-assisted carbonylation with carbon monoxide and oxidation with molecular oxygen under mild conditions. *Synthesis* **2009**, 2492–2496. [[CrossRef](#)]
17. Kim, S.H.; Hong, S.H. Ruthenium-catalyzed urea synthesis using methanol as the C1 source. *Org. Lett.* **2016**, *18*, 212–215. [[CrossRef](#)] [[PubMed](#)]
18. Thalluri, K.; Manne, S.R.; Dev, D.; Mandal, B. Ethyl 2-cyano-2-(4-nitrophenylsulfonyloxyimino) acetate-mediated Lossen rearrangement: Single-pot racemization-free synthesis of hydroxamic acids and ureas from carboxylic acids. *J. Org. Chem.* **2014**, *79*, 3765–3775. [[CrossRef](#)] [[PubMed](#)]
19. Vinogradova, E.V.; Fors, B.P.; Buchwald, S.L. Palladium-catalyzed cross-coupling of aryl chlorides and triflates with sodium cyanate: A practical synthesis of unsymmetrical ureas. *J. Am. Chem. Soc.* **2012**, *134*, 11132–11135. [[CrossRef](#)] [[PubMed](#)]
20. Le, H.V.; Ganem, B. Trifluoroacetic anhydride-catalyzed oxidation of isonitriles by DMSO: A rapid, convenient synthesis of isocyanates. *Org. Lett.* **2011**, *13*, 2584–2585. [[CrossRef](#)] [[PubMed](#)]
21. Smith, K.; El-Hiti, G.A.; Alshammari, M.B. Directed lithiation of *N'*-[2-(4-methoxyphenyl)ethyl]-*N,N*-dimethylurea and *tert*-butyl [2-(4-methoxyphenyl)ethyl]carbamate. *Synthesis* **2014**, *46*, 394–402. [[CrossRef](#)]
22. Smith, K.; El-Hiti, G.A.; Alshammari, M.B.; Fekri, A. Control of site of lithiation of 3-(aminomethyl)pyridine derivatives. *Synthesis* **2013**, *45*, 3426–3434. [[CrossRef](#)]
23. Smith, K.; El-Hiti, G.A.; Alshammari, M.B. Lithiation and substitution of *N'*-(ω -phenylalkyl)-*N,N*-dimethylureas. *Synthesis* **2012**, *44*, 2013–2022. [[CrossRef](#)]
24. Smith, K.; El-Hiti, G.A.; Alshammari, M.B. Variation in the site of lithiation of 2-(2-methylphenyl)ethanamine derivatives. *J. Org. Chem.* **2012**, *77*, 11210–11215. [[CrossRef](#)] [[PubMed](#)]
25. Smith, K.; El-Hiti, G.A.; Hegazy, A.S. Lateral lithiation of *N'*-(2-methylbenzyl)-*N,N*-dimethylurea and *N*-(2-methylbenzyl)pivalamide: Synthesis of tetrahydroisoquinolines. *Synthesis* **2010**, 1371–1380. [[CrossRef](#)]
26. Taylor, R.G.D.; Yeo, B.R.; Hallett, A.J.; Kariuki, B.M.; Pope, S.J.A. An organometallic complex revealing an unexpected, reversible, temperature induced SC-SC transformation. *CrystEngComm* **2014**, *16*, 4641–4652. [[CrossRef](#)]
27. Khoj, M.A.; Hughes, C.E.; Harris, K.D.M.; Kariuki, B.M. Polymorphism in a *trans*-cinnamic acid derivative exhibiting two distinct β -type phases: Structural properties, [2 + 2] photodimerization reactions, and polymorphic phase transition behavior. *Cryst. Growth Des.* **2013**, *13*, 4110–4117. [[CrossRef](#)]
28. Yates, J.L.R.; Sparkes, H.A. 4-Bromo-*trans*-cinnamic acid: Structural characterisation and crystallographic investigation into the solid state [2 + 2] cycloaddition reaction and temperature induced phase transition. *CrystEngComm* **2013**, *15*, 3547–3553. [[CrossRef](#)]
29. Palmer, B.A.; Kariuki, B.M.; Morte-Rodenas, A.; Harris, K.D.M. Structural rationalization of the phase transition behavior in a solid organic inclusion compound: bromocyclohexane/thiourea. *Cryst. Growth Des.* **2012**, *12*, 577–582. [[CrossRef](#)]
30. Pete, U.D.; Dikundwar, A.G.; Sharma, V.M.; Gejji, S.P.; Bendre, R.S.; Guru Row, T.N. Partial rotation of the isopropyl group in the solid state: Single-crystal-to-single-crystal phase transformation in a carvacrol derivative. *CrystEngComm* **2015**, *17*, 7482–7485. [[CrossRef](#)]
31. Rubin-Preminger, J.M.; Bernstein, J.; Harris, R.K.; Evans, I.R.; Ghi, P.Y. [*R,S*]-ethambutol dihydrochloride: Variable-temperature studies of a dimorphic system with very similar packing. *J. Pharm. Sci.* **2004**, *93*, 2810–2819. [[CrossRef](#)] [[PubMed](#)]
32. Sorensen, A.M.; Simonsen, O. The structures of (*R,S*)-2,2'-(1,2-ethanedioldiimino)bis-1-butanol dihydrochloride at 295 and 333 K. A reversible phase transition. *Acta Crystallogr. C* **1989**, *45*, 4. [[CrossRef](#)]
33. Das, D.; Engel, E.; Barbour, L.J. Reversible single-crystal to single-crystal polymorphic phase transformation of an organic crystal. *Chem. Commun. (Cambridge UK)* **2010**, *46*, 1676–1678. [[CrossRef](#)] [[PubMed](#)]
34. Hu, C.; Englert, U. Crystal-to-crystal transformation from a chain polymer to a two-dimensional network at low temperatures. *Angew. Chem. Int. Ed.* **2005**, *44*, 2281–2283. [[CrossRef](#)] [[PubMed](#)]
35. Zhang, J.-P.; Lin, Y.-Y.; Zhang, W.-X.; Chen, X.-M. Temperature- or guest-induced drastic single-crystal-to-single-crystal transformations of a nanoporous coordination polymer. *J. Am. Chem. Soc.* **2005**, *127*, 14162–14163. [[CrossRef](#)] [[PubMed](#)]

36. Dunitz, J.D. Phase transitions in molecular crystals from a chemical viewpoint. *Pure Appl. Chem.* **1991**, *63*, 177–185. [[CrossRef](#)]
37. Meijer, M.D.; Gebbink, R.J.M.K.; van Koten, G. Solid-gas interactions between small gaseous molecules and transition metals in the solid state. Toward sensor applications. *Perspect. Supramol. Chem.* **2003**, *7*, 375–386.
38. Sheldrick, G.M. A short history of SHELX. *Acta Crystallogr. Sect. A Found. Crystallogr.* **2008**, *64*, 112–122. [[CrossRef](#)] [[PubMed](#)]



© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).